<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Reported-in-House" dms-id="H38C986EB86D94E75A50B546806490A60" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 501 RH: Block, Report, and Suspend Suspicious Shipments Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-05-17</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">IB</distribution-code><calendar display="yes">Union Calendar No. 46</calendar><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 501</legis-num><associated-doc role="report" display="yes">[Report No. 118–66, Part I]</associated-doc><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230125">January 25, 2023</action-date><action-desc><sponsor name-id="H001086">Mrs. Harshbarger</sponsor> (for herself and <cosponsor name-id="D000624">Mrs. Dingell</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HJU00">the Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><action display="yes"><action-date date="20230517">May 17, 2023</action-date><action-desc>Additional sponsors: <cosponsor name-id="H001091">Mrs. Hinson</cosponsor>, <cosponsor name-id="L000590">Ms. Lee of Nevada</cosponsor>, <cosponsor name-id="T000487">Ms. Tokuda</cosponsor>, <cosponsor name-id="C001133">Mr. Ciscomani</cosponsor>, <cosponsor name-id="S001216">Ms. Schrier</cosponsor>, and <cosponsor name-id="M001221">Mr. Molinaro</cosponsor></action-desc></action><action display="yes"><action-date date="20230517">May 17, 2023</action-date><action-desc>Reported from the <committee-name added-display-style="italic" committee-id="HIF00" deleted-display-style="strikethrough">Committee on Energy and Commerce</committee-name> with an amendment</action-desc><action-instruction>Strike out all after the enacting clause and insert the part printed in italic</action-instruction></action><action display="yes"><action-date date="20230517">May 17, 2023</action-date><action-desc>Committee on <committee-name committee-id="HJU00">the Judiciary</committee-name> discharged; committed to the Committee of the Whole House on the State of the Union and ordered to be printed</action-desc><action-instruction>For text of introduced bill, see copy of bill as introduced on January 25, 2023</action-instruction></action><action><action-desc><pagebreak></pagebreak></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Controlled Substances Act to require registrants to decline to fill certain suspicious orders, and for other purposes.<pagebreak></pagebreak></official-title></form><legis-body display-enacting-clause="yes-display-enacting-clause" changed="added" style="OLC" committee-id="HIF00" reported-display-style="italic" id="HE9D70A956CD84014AA9074034FEE3BCD"><section id="HBD5D1520DCEA4645A5147B623D07A711" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Block, Report, and Suspend Suspicious Shipments Act</short-title></quote>.</text></section><section id="H1EB25AC852CB4E1B828A54539B297B21" section-type="subsequent-section"><enum>2.</enum><header>Block, report, and suspend suspicious orders</header><subsection id="HB6A792454C0D4CB8AA28BA610B1D4DEC"><enum>(a)</enum><header>Clarification of process for registrants To exercise due diligence upon discovering a suspicious order</header><text display-inline="yes-display-inline">Section 312(a) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/832">21 U.S.C. 832(a)</external-xref>) is amended—</text><paragraph id="H6723D9D7924B47CAA6DFF7C8A1A133F1"><enum>(1)</enum><text>in paragraph (2), by striking <quote>and</quote> at the end; and</text></paragraph><paragraph id="H993123017EC344E2A411542E2D393215"><enum>(2)</enum><text>by striking paragraph (3) and inserting the following paragraphs:</text><quoted-block display-inline="no-display-inline" id="H0F3B722B33144FCDA41CEF0F1585438C" style="OLC" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="H68120F24344143CEAFBBF58A06295FD9"><enum>(3)</enum><text display-inline="yes-display-inline">determine whether an order or series of orders is suspicious, taking into consideration—</text><subparagraph id="H59C60F6A21274D06ADCD626E7A641542"><enum>(A)</enum><text display-inline="yes-display-inline">any unusual size, pattern, or frequency of the order or series of orders; and</text></subparagraph><subparagraph id="H6FB43D4A1689430F905E39E17D143A7A"><enum>(B)</enum><text display-inline="yes-display-inline">any customer business model, dispensing patterns, prior orders, or other characteristics that may indicate the order or series of orders is suspicious, despite the particular order or series of orders not exhibiting an unusual size, pattern, or frequency; and</text></subparagraph></paragraph><paragraph id="HF049D491B54B4E0A9AA412774E04EA74"><enum>(4)</enum><text display-inline="yes-display-inline">upon discovering suspicious circumstances regarding an order or series of orders, and in a manner consistent with the other requirements of this section—</text><subparagraph id="HF05BED1D88974DBF98ACEBF13A1C1254"><enum>(A)</enum><text display-inline="yes-display-inline">decline to fill the order or series of orders, establish and maintain (for not less than a period to be determined by the Administrator of the Drug Enforcement Administration) a record of the order or series of orders, and notify the Administrator of the Drug Enforcement Administration for the purpose of including information on such order or series of orders in the centralized database established under subsection (b)(1); or</text></subparagraph><subparagraph id="HA9FC32989FAF4C1B82ABD8C4B54DCC3E"><enum>(B)</enum><text>exercise due diligence as appropriate and—</text><clause id="HAC07E228CF5E4650B759268CBD95555B"><enum>(i)</enum><subclause commented="no" display-inline="yes-display-inline" id="H2DE9C0F62D5D43419F5EF9B9DCEDDA57"><enum>(I)</enum><text display-inline="yes-display-inline">if the due diligence fails to dispel all of the indicators that give rise to the suspicion that, if the order or series of orders is filled, the drugs that are the subject of the order or series of orders are likely to be diverted, decline to fill the order or series of orders; or</text></subclause><subclause id="H6C5D5D708B084265BF4A77FDABCEA0B4" indent="up1"><enum>(II)</enum><text>if the due diligence does dispel all such indicators, fill the order or series of orders;</text></subclause></clause><clause id="H002453B3C5F24576A610CB12AC4F2B1E"><enum>(ii)</enum><text display-inline="yes-display-inline">establish and maintain (for not less than a period to be determined by the Administrator of the Drug Enforcement Administration) a record of the order or series of orders and the due diligence that was performed; and</text></clause><clause id="HA0CA6AF53A9F4A87964CB8B7053A8640"><enum>(iii)</enum><text display-inline="yes-display-inline">notify the Administrator of the Drug Enforcement Administration for the purpose of including information on such order or series of orders in the centralized database established under subsection (b)(1), including any indicators giving rise to the suspicion that, if the order or series of orders is filled, the drugs that are the subject of the order or series of orders are likely to be diverted.</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H449A82FFB46D444880E0E4F4BC3C57CF"><enum>(b)</enum><header>Regulations</header><text display-inline="yes-display-inline">Not later than 1 year after the date of enactment of this Act, for purposes of section 312(a)(4) of the Controlled Substances Act, as inserted by subsection (a), the Attorney General of the United States shall promulgate a final regulation specifying—</text><paragraph id="HB31529CD80A346279F3B677D662FDDD0"><enum>(1)</enum><text>the indicators that give rise to a suspicion that, if an order or series of orders is filled, the drugs that are the subject of the order or series of orders are likely to be diverted; </text></paragraph><paragraph id="HED2FF9302E5B499EBFCF926CCA9BBDC1"><enum>(2)</enum><text display-inline="yes-display-inline">a definition of due diligence; and</text></paragraph><paragraph id="HCACE2E3B395148F88BED9B20A1FA0FD4"><enum>(3)</enum><text display-inline="yes-display-inline">in the case of a registrant that dispels all of the indicators giving rise to a suspicious order or series of orders, the circumstances in which the registrant is not required to file the notification under such section 312(a)(4). </text></paragraph></subsection><subsection id="H45FD38E928514579B19E5F0CEF11EE5A"><enum>(c)</enum><header>Penalty</header><text>Section 402(a)(5) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/842">21 U.S.C. 842(a)(5)</external-xref>) is amended by inserting before the semicolon at the end the following: <quote>, including any such violation of section 312(a)(4)</quote>. </text></subsection><subsection id="HA418A61445164E528BCA500A33D468D1"><enum>(d)</enum><header>Applicability</header><text display-inline="yes-display-inline">Section 312(a)(4) of the Controlled Substances Act, as inserted by subsection (a), shall apply beginning on the day that is 1 year after the date of enactment of this Act. Until such day, section 312(a)(3) of the Controlled Substances Act shall apply as such section 312(a)(3) was in effect on the day before the date of enactment of this Act.</text></subsection><subsection id="H7A430FA3D1474EFAAB313EED81EB32B1"><enum>(e)</enum><header>Sense of Congress</header><text display-inline="yes-display-inline">It is the sense of Congress that—</text><paragraph id="HFF2A77732AB34FC8AD8F837F2F01028C"><enum>(1)</enum><text>medications for opioid use disorder significantly reduce the risk of overdose death; and</text></paragraph><paragraph id="H539BE821A9814308BF76850263E16704"><enum>(2)</enum><text>the requirements of this Act are not intended to impair access to controlled substances primarily used to treat opioid use disorder.</text></paragraph></subsection></section></legis-body><endorsement display="yes"><action-date>May 17, 2023</action-date><action-desc>Reported from the <committee-name added-display-style="italic" committee-id="HIF00" deleted-display-style="strikethrough">Committee on Energy and Commerce</committee-name> with an amendment</action-desc><action-date>May 17, 2023</action-date><action-desc>Committee on <committee-name committee-id="HJU00">the Judiciary</committee-name> discharged; committed to the Committee of the Whole House on the State of the Union and ordered to be printed</action-desc></endorsement></bill> 

